Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins

CONCLUSION: Treatment with liraglutide induces a significant reduction of plasma PCSK9 in patients with T2DM not on statins. This is in line with the acceleration of LDL catabolism that has been observed with liraglutide. However, this decrease in plasma PCSK9 is significantly influenced by glycaemic control and is not observed in patients with poorly controlled T2DM.PMID:34551355 | DOI:10.1016/j.diabet.2021.101284

Source: Diabetes and Metabolism - September 22, 2021 Category: Endocrinology Authors: Bruno Verg ès Jonathan Hassid Alexia Rouland Benjamin Bouillet Isabelle Simoneau Jean-Michel Petit Laurence Duvillard Source Type: research